US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist

9.230
-0.250-2.64%

Close May 10 16:00 ET

9.230
0.0000.00%

Post 16:20 ET

2.73BMarket Cap-18836P/E (TTM)

Amicus Therapeutics Stock Forum

Moomoo AI

Feb 7 20:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3 19:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Shares Climb 28% But Its Business Is Yet to Catch Up

Mini0n

Sep 29, 2023 00:13

$Amicus Therapeutics(FOLD.US)$ Good thing this didn't have any bad news, jesus

73015995

Sep 28, 2023 23:06

$Amicus Therapeutics(FOLD.US)$ FDA approval 🚀🙏🏻

Mini0n

Sep 28, 2023 20:50

$Amicus Therapeutics(FOLD.US)$ News halt...... watching

Mantou

Aug 16, 2023 11:56

Amicus announces U.K. approval and launch of Pompe disease therapy

$Amicus Therapeutics(FOLD.US)$

Alvinnnnnnngenius

Aug 15, 2023 19:37

$Amicus Therapeutics(FOLD.US)$ Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.

WallStreetYoda

Oct 14, 2022 03:09

$Amicus Therapeutics(FOLD.US)$ Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more